This means a growth, like a tumor or cancer, has developed in the parts of your body that make and store bile. This includes the liver, gallbladder, and bile ducts. It's important to get checked if you have a growth in this area.
Every report comes from a Lived member, sent anonymously.
Have you tried Gemcitabine for Biliary Tract Neoplasms?
Biliary tract neoplasms are tumors of the system that carries bile, a digestive fluid made by the liver, through a network of ducts to the gallbladder for storage and on to the small intestine. In practice the term usually refers to biliary tract cancers. These include bile duct cancer (cholangiocarcinoma), which can start in ducts inside the liver or outside it, gallbladder cancer, and cancer of the ampulla of Vater, the opening where the bile duct empties into the intestine. All of them are uncommon. Many of the symptoms come from a tumor narrowing a bile duct so bile backs up into the blood. That causes jaundice (yellowing of the skin and whites of the eyes), dark urine, pale or clay-colored stools and itchy skin. Pain in the upper abdomen, fever, nausea and unexplained weight loss can also occur. Early tumors often cause no symptoms at all, and tumors deep inside the liver may not cause jaundice until late. This is a major reason these cancers are often found after they have already spread.
Long-term inflammation and injury of the bile ducts or gallbladder is the common thread behind most known risk factors. For bile duct cancer, these include primary sclerosing cholangitis (a disease in which the bile ducts become inflamed and scarred), cysts of the bile ducts, stones in the bile ducts or inside the liver, cirrhosis, chronic hepatitis B or C infection, and ulcerative colitis. Infection with liver flukes, parasitic worms common in parts of East and Southeast Asia, helps explain why bile duct cancer is far more common in those regions. Gallbladder cancer is more common in women and in Native American people. Gallstones are its most common risk factor, yet most people with gallstones never develop gallbladder cancer. Obesity, type 2 diabetes and some long-term infections of the gallbladder are also linked to higher risk. These are associations, not certain causes. Many people with a risk factor never develop cancer, and many people diagnosed have no known risk factor at all.
There is no routine screening test for most people, so diagnosis usually starts with symptoms such as jaundice, or with something unexpected on a scan. Gallbladder cancer is often discovered when a gallbladder removed for gallstones is examined under a microscope. Blood tests check liver function. A high bilirubin (the yellow pigment that causes jaundice) and alkaline phosphatase (a liver and bile duct enzyme) point to blocked bile flow, though stones and other conditions can do the same. Tumor markers called CA 19-9 and CEA may be raised, but they are not specific enough to diagnose cancer on their own. They are more useful for tracking how the disease responds to treatment. Imaging shows where the tumor is and how far it reaches. This usually means a CT scan, an MRI, or MRCP, an MRI technique that maps the bile ducts. Procedures that pass a thin scope down the throat, such as ERCP (endoscopic retrograde cholangiopancreatography) and endoscopic ultrasound, can take tissue samples and, if a duct is blocked, place a stent (a small tube) to let bile drain. A biopsy confirms the diagnosis, although when a tumor looks removable, the tissue is sometimes examined only after surgery. The central question is whether the cancer can be completely removed by surgery, which shapes everything that follows. For advanced cancer, guidelines also recommend molecular testing of the tumor, which looks for specific gene changes (such as in FGFR2, IDH1 or HER2) that can make targeted medicines an option.
Surgery that removes the whole tumor along with nearby lymph nodes is the only treatment that offers a chance of cure. Depending on where the cancer is, it may mean removing part of the bile duct, part of the liver, or the gallbladder with surrounding liver, or a Whipple procedure, which removes the lower bile duct with the head of the pancreas and part of the small intestine. These are major operations, best done at experienced centers, and a person's overall health matters as much as the tumor in deciding whether surgery is safe. After surgery, several months of chemotherapy pills (usually capecitabine) are commonly offered to lower the chance of the cancer returning, although the benefit is moderate rather than certain. Most people are diagnosed when surgery cannot remove the cancer. For them, the usual first treatment combines two chemotherapy drugs, gemcitabine and cisplatin, with an immunotherapy drug: durvalumab (Imfinzi) or pembrolizumab (Keytruda). Immunotherapy helps the immune system recognize and attack cancer cells. In large trials, adding it lengthened average survival by roughly two months, and some people benefit for considerably longer. Treatment aims to control the cancer and its symptoms rather than cure it. If the cancer grows despite first treatment, further chemotherapy is an option. When molecular testing finds a matching gene change, targeted medicines can be used, such as pemigatinib or futibatinib for FGFR2 changes, ivosidenib for IDH1 changes, or HER2-directed drugs such as zanidatamab (Ziihera) for HER2 changes. Each matching change is found in a minority of tumors: FGFR2 and IDH1 changes mainly in bile duct cancers inside the liver, and HER2 changes more often in gallbladder cancer and bile duct cancers outside the liver. When they apply, these medicines can shrink or control tumors that have stopped responding to chemotherapy. Radiation, local treatments such as ablation for small liver tumors, and clinical trials may also have a role. Relieving a blocked bile duct is often as important as treating the cancer. A stent placed by endoscopy, or a drain placed through the skin into the liver, can clear jaundice and itching, lower the risk of infection and make chemotherapy safer to give.
Biliary tract cancers are serious, and the outlook depends heavily on whether the cancer can be removed. Even after successful surgery, the cancer comes back in many people, so follow-up typically includes visits, blood tests and scans every 3 to 6 months for the first two years and less often after that, for up to five years. For people with advanced cancer, treatment is usually ongoing and organized in cycles, with scans every two to three months to check whether it is working. Fatigue, appetite loss, weight loss and side effects of chemotherapy can affect daily routines, and the plan is often adjusted to balance cancer control with how a person feels. Immunotherapy can occasionally cause inflammation in organs such as the bowel, liver, lungs or thyroid, which the care team watches for. People with stents may need them replaced over time, because stents can become blocked. Palliative care, which focuses on symptoms, nutrition and quality of life, can be added at any point alongside cancer treatment rather than only at the end. Because these cancers are uncommon, care at a center with a specialist team experienced in liver and bile duct surgery and oncology can make a meaningful difference.
See a clinician promptly about new yellowing of the skin or eyes, dark urine, pale stools, persistent itching, or unexplained weight loss or upper abdominal pain. These usually have other causes, but they need to be checked. For people with a known biliary tract cancer, a temperature of 38°C (about 100.4°F) or higher, or shaking chills, means contacting the care team right away rather than waiting for the next visit. During chemotherapy, fever can be the first sign of a serious infection, because treatment lowers the white blood cells that fight infection. With a stent or drain in place, fever, chills or jaundice that returns or deepens can also mean a blocked stent or a bile duct infection. This needs assessment the same day, because these infections can spread to the blood quickly. If fever or chills come with confusion, fainting, very fast breathing or heartbeat, or feeling severely unwell, go to an emergency department or call 911. During immunotherapy, report new diarrhea, cough, shortness of breath or rash to the care team quickly.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Biliary Tract Neoplasms is like, what's helped you, or ask the community a question.